TD Asset Management Inc. increased its position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 20.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 38,078 shares of the biotechnology company’s stock after buying an additional 6,400 shares during the period. TD Asset Management Inc. owned 0.08% of Aimmune Therapeutics worth $783,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares during the period. American International Group Inc. boosted its position in Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,070 shares during the period. Nationwide Fund Advisors boosted its position in Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 3,851 shares during the period. Strs Ohio boosted its position in Aimmune Therapeutics by 6.1% in the second quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock valued at $711,000 after buying an additional 2,000 shares during the period. Finally, Swiss National Bank boosted its position in Aimmune Therapeutics by 17.5% in the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after buying an additional 5,500 shares during the period. Hedge funds and other institutional investors own 72.90% of the company’s stock.

Shares of Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at 21.00 on Wednesday. Aimmune Therapeutics, Inc. has a 1-year low of $14.01 and a 1-year high of $27.31. The company’s market cap is $1.06 billion. The firm has a 50-day moving average price of $20.60 and a 200 day moving average price of $20.06.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.01. On average, equities analysts anticipate that Aimmune Therapeutics, Inc. will post ($2.71) earnings per share for the current year.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-stake-increased-by-td-asset-management-inc/1530803.html.

Several equities analysts have recently weighed in on AIMT shares. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Piper Jaffray Companies set a $38.00 price objective on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 27th. Wedbush reiterated an “ourperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, August 14th. Finally, BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Aimmune Therapeutics has an average rating of “Hold” and an average price target of $32.50.

In other news, insider Stephen George Dilly sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total value of $1,073,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Douglas T. Sheehy sold 7,460 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $21.66, for a total value of $161,583.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 188,470 shares of company stock worth $3,942,092. Insiders own 24.56% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.